EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Diffusion-weighted MRI-Derived ADC and tumor volume as predictive imaging markers for neoadjuvant chemotherapy response in muscle-invasive bladder cancer

Abolfazl Razzaghdoust, Anya Jafari, Arash Mahdavi, Bahram Mofid, Abbas Basiri

BMC Medical Imaging · 2025

DOI: 10.1186/s12880-024-01547-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BMC Medical Imaging, 2025. Verfasst von Abolfazl Razzaghdoust und 4 weiteren Autor:innen. Beteiligte Einrichtung: Urology and Nephrology Research Center, Research Institute for Urology and Nephrology, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Diffusion Magnetic Resonance Imaging, Neoadjuvant Therapy, Tumor Burden. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: This prospective study tested the hypothesis that the apparent diffusion coefficient (ADC) value and tumor volume (TV) measured in diffusion-weighted magnetic resonance imaging (DW-MRI) before, during, and after the treatment are quantitative imaging markers to assess tumor response in muscle-invasive bladder cancer (MIBC) patients undergoing neoadjuvant chemotherapy (NAC). METHODS: Multi-parametric MRI was prospectively done for MIBC patients at 3 time points. Pre-treatment ADC value, pre-treatment TV, as well as, percent of changes (ΔADC%, and ΔTV%) in these parameters at mid- and post-treatment relative to baseline were calculated and compared between the patients with and without clinical complete response (CR). Also, further analysis was carried out based on the groups of patients with and without overall response (OR). Two different methods of ADC estimation including single-slice ADC measurement (ADCsingle-slice) and whole-lesion ADC measurement (ADCwhole-lesion) were used. RESULTS: A total of 50 eligible patients were included in the analysis. Of these, 20 patients (40%) showed clinical CR to treatment, while 30 (60%) did not. Our results showed that although there was no significant difference between the two groups of patients with and without CR in terms of mid-treatment ΔADC% and mid-treatment ΔTV%, significant differences were observed in terms of the pre-treatment ADC (p 0.9, P < 0.001). CONCLUSION: Pre-treatment ADC, pre-treatment TV, post-treatment ΔADC%, and post-treatment ΔTV% could be considered as promising quantitative imaging markers of tumor response in MIBC patients undergoing NAC. Moreover, mid-treatment ΔADC% and mid-treatment ΔTV% should not be used as predictors of tumor response in these patients. Further larger studies are required to confirm these results.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsDiffusion Magnetic Resonance ImagingNeoadjuvant TherapyTumor BurdenHumansMaleFemaleAgedMiddle AgedProspective StudiesTreatment OutcomeNeoplasm InvasivenessAged, 80 and overChemotherapy, Adjuvant

Stichwörter der Autor:innen

Apparent diffusion coefficientDiffusion-weighted magnetic resonance imagingMuscle-invasive bladder cancerNeoadjuvant chemotherapyTumor response

Autor:innen und Institutionen

  • Urology and Nephrology Research Center, Research Institute for Urology and Nephrology, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Department of Radiation Oncology, Shohada-e Tajrish Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Department of Radiology, University of Washington School of Medicine, Seattle, WA, USA.
  • Department of Radiation Oncology, Shohada-e Tajrish Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. mofid429@sbmu.ac.ir.
  • Urology and Nephrology Research Center, Research Institute for Urology and Nephrology, Shahid Labbafinejad Hospital, Shahid Beheshti University of Medical Sciences, No.103, Shahid Jafari St., Pasdaran Ave., Tehran, 1666…

Zitieren

APA

Razzaghdoust, A., Jafari, A., Mahdavi, A., Mofid, B., & Basiri, A. (2025). Diffusion-weighted MRI-Derived ADC and tumor volume as predictive imaging markers for neoadjuvant chemotherapy response in muscle-invasive bladder cancer. BMC Medical Imaging. https://doi.org/10.1186/s12880-024-01547-3

Vancouver

Razzaghdoust A, Jafari A, Mahdavi A, Mofid B, Basiri A. Diffusion-weighted MRI-Derived ADC and tumor volume as predictive imaging markers for neoadjuvant chemotherapy response in muscle-invasive bladder cancer. BMC Medical Imaging. 2025. doi:10.1186/s12880-024-01547-3

BibTeX
@article{Razzaghdoust2025,
  author = {Razzaghdoust, Abolfazl and Jafari, Anya and Mahdavi, Arash and Mofid, Bahram and Basiri, Abbas},
  title = {Diffusion-weighted MRI-Derived ADC and tumor volume as predictive imaging markers for neoadjuvant chemotherapy response in muscle-invasive bladder cancer},
  journal = {BMC Medical Imaging},
  year = {2025},
  doi = {10.1186/s12880-024-01547-3}
}
Kostenlos starten →